IPH-64

Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Innate Pharma reported positive Phase 2 results for lacutamab in mycosis fungoides, engaging with the FDA for potential accelerated approval.